Month: August 2017

Data-Driven Programmatic Approach to Analysis of Basophil Activation Tests

Flow CAST® ELISA: Sarita U. Patel. Data-Driven Programmatic Approach to Analysis of Basophil Activation Tests Cytometry B Clin Cytom. 2017 Jun 15. doi: 10.1002/cyto.b.21537. PMID: 28618453. Highlights from this Publication “We present a novel data-driven flow cytometric platform for the analysis of clinical basophil activation testing, providing a high throughput objective approach to basophil activation analysis." Read Citation
Continue Reading

Diagnostic Accuracy of Fecal Calprotectin in Assessing the Severity of Inflammatory Bowel Disease: From Laboratory to Clinic

BÜHLMANN fCAL® ELISA: S. Moein, D. Quujeq et al. Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: From laboratory to clinic. Caspian J Intern Med 2017; 8(3):178-182 DOI: 10.22088/cjim.8.3.178. Highlights from this Publication “ The current study also suggested 78.4 µg/g as the cut-off level for FC by 100% sensitivity and
Continue Reading

Protected: Announcing Enhancement to Quantum Blue® fCAL (Calprotectin) High Range Assay

There is no excerpt because this is a protected post.

Continue Reading

Integration of Controls into BUHMANN Quantum Blue® Assays

Quantum Blue® Lateral Flow Assays: Simple, Fast, Accurate Quantitative Results Now Even More Convenient with 2 Lot Specific Ready-to-use Controls! Available NOW with Integrated Controls: Quantum Blue® Infliximab Assay The BÜHLMANN Quantum Blue® Infliximab is the ONLY  quantitative rapid test in the market for infliximab that can provide fast, reliable information for infliximab.  The test is designed for the selective
Continue Reading

Protected: Quantum Blue® fCAL Assay Highlights

There is no excerpt because this is a protected post.

Continue Reading
Sign Up for BUHLMANN Updates!

Enter your email and stay on top of things,